Trial results for a study investigating gut organoid and microbiome interactions in Hypertension were posted on ClinicalTrials.gov on 2025-09-29, identifying 29 differentially expressed genes in the gut epithelium.

Background

Hypertension is a common chronic condition that significantly increases the risk of heart disease, stroke, and kidney failure. While traditional risk factors and treatments are well-established, emerging research explores the role of the gut microbiome and gut epithelium in its pathogenesis. This study aimed to investigate fundamental differences in the gut epithelium between individuals with hypertension and normotensive subjects, specifically by examining gene expression profiles, which could offer new insights into the disease's mechanisms.

Trial design

This completed study enrolled 35 participants to investigate conditions including Gut Inflammation and Hypertension. The study's objective was to compare basic properties and gene expression profiles of gut epithelia derived from biopsy samples of hypertensive and normotensive individuals undergoing clinically indicated colonoscopy.

Key results

What this means

The identification of specific differentially expressed genes in the gut epithelium of individuals with hypertension suggests a potential biological link between gut health and this cardiovascular condition. While this study was observational and involved a small cohort of 35 participants, these findings contribute to a growing understanding of hypertension's complex pathophysiology. Further research would be needed to determine the functional significance of these gene expression differences and their potential as targets for future diagnostic tools or therapeutic interventions.

Source

The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04497727, titled "Gut Organoid and Microbiome Interactions in Hypertension", were posted on 2025-09-29 on clinicaltrials.gov.